Stock Events

Stock Events

CorMedix 

$7.49
119
+$0.30+4.17% Thursday 20:00
+$0.16+2.14%Thursday 23:45After hours

Statistics

Day High
7.51
Day Low
7.48
52W High
14.96
52W Low
6.13
Volume
30,241
Avg. Volume
-
Mkt Cap
587.6M
P/E Ratio
3.87
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.25
0.25
0.76
1.26
Expected EPS
0.238
Actual EPS
N/A

Financials

52.31%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
311.71MRevenue
163.06MNet Income

Analyst Ratings

15.00Average Price Target
The highest estimate is 19.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRMD. It's not an investment recommendation.
Amazon
25
AMZN
Microsoft
22
MSFT
Alphabet
22
GOOGL
NVIDIA
20
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is a global pharmaceutical company that competes with CorMedix in the development of drugs for infectious diseases, including those targeted by CorMedix's lead product, DefenCath.
Merck
MRK
Mkt Cap305.12B
Merck & Co., Inc. is involved in the discovery, development, manufacturing, and marketing of pharmaceuticals that directly compete with CorMedix's portfolio, especially in the antimicrobial space.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its pharmaceutical segment, competes in the development and marketing of products that could be used in similar indications as CorMedix's, including infection prevention.
Abbott Laboratories
ABT
Mkt Cap163.61B
Abbott Laboratories offers a wide range of healthcare products that compete with CorMedix, particularly in the area of medical devices and diagnostics for infectious diseases.
AMGEN
AMGN
Mkt Cap196.12B
Amgen competes with CorMedix in the biopharmaceutical field, focusing on innovative treatments that could overlap with CorMedix's market, especially in the area of infection control.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas that compete with CorMedix, particularly in the treatment of infectious diseases.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol-Myers Squibb is involved in the discovery and development of drugs in areas that could compete with CorMedix, including therapies for preventing and treating infections.
Novartis
NVS
Mkt Cap293.94B
Novartis AG competes with CorMedix in the global healthcare market, particularly in the development and marketing of products for the treatment of various diseases, including those targeted by CorMedix.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca is a global, science-led biopharmaceutical business that competes with CorMedix in the development and commercialization of medicines for various diseases, including infections.
Sanofi
SNY
Mkt Cap104.13B
Sanofi is a global healthcare leader that competes with CorMedix in the areas of pharmaceuticals, including the development of treatments for infections similar to those targeted by CorMedix.

About

CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Show more...
CEO
Mr. Joseph Todisco MBA
Employees
191
Country
United States
ISIN
US21900C3088

Listings

XNAS
US
CRMD
STU
DE
19KA.STU
BOATS
BOATS
CRMD.BOATS
MU
DE
19KA.MU

0 Comments

Share your thoughts

FAQ

What is CorMedix stock price today?▼
The current price of CRMD is $7.49 USD — it has increased by +4.17% in the past 24 hours. Watch CorMedix stock price performance more closely on the chart.
What is CorMedix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange CorMedix stocks are traded under the ticker CRMD.
Is CorMedix stock price growing?▼
CRMD stock has fallen by -4.83% compared to the previous week, the month change is a -11.57% fall, over the last year CorMedix has showed a -35.82% decrease.
What is CorMedix market cap?▼
Today CorMedix has the market capitalization of 587.6M
When is the next CorMedix earnings date?▼
CorMedix is going to release the next earnings report on August 13, 2026.
What were CorMedix earnings last quarter?▼
CRMD earnings for the last quarter are 0.43 USD per share, whereas the estimation was 0.34 USD resulting in a +25.42% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is CorMedix revenue for the last year?▼
CorMedix revenue for the last year amounts to 311.71M USD.
What is CorMedix net income for the last year?▼
CRMD net income for the last year is 163.06M USD.
How many employees does CorMedix have?▼
As of July 31, 2026, the company has 191 employees.
In which sector is CorMedix located?▼
CorMedix operates in the Health & Wellness sector.
When did CorMedix complete a stock split?▼
The last stock split for CorMedix was on March 26, 2019 with a ratio of 1:5.
Where is CorMedix headquartered?▼
CorMedix is headquartered in Parsippany, United States.